- Home
- GSIW vs BCAB Comparison
GSIW vs BCAB Comparison
Compare GSIW & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- BCAB
- Stock Information
- Founded
- GSIW 2016
- BCAB 2007
- Country
- GSIW Hong Kong
- BCAB United States
- Employees
- GSIW N/A
- BCAB N/A
- Industry
- GSIW
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- GSIW
- BCAB Health Care
- Exchange
- GSIW Nasdaq
- BCAB Nasdaq
- Market Cap
- GSIW 27.2M
- BCAB 22.3M
- IPO Year
- GSIW 2023
- BCAB 2020
- Fundamental
- Price
- GSIW $1.54
- BCAB $0.39
- Analyst Decision
- GSIW
- BCAB Buy
- Analyst Count
- GSIW 0
- BCAB 2
- Target Price
- GSIW N/A
- BCAB $1.00
- AVG Volume (30 Days)
- GSIW 1.7M
- BCAB 520.0K
- Earning Date
- GSIW 01-01-0001
- BCAB 08-07-2025
- Dividend Yield
- GSIW N/A
- BCAB N/A
- EPS Growth
- GSIW N/A
- BCAB N/A
- EPS
- GSIW N/A
- BCAB N/A
- Revenue
- GSIW $1,313,795.00
- BCAB $11,000,000.00
- Revenue This Year
- GSIW N/A
- BCAB N/A
- Revenue Next Year
- GSIW N/A
- BCAB N/A
- P/E Ratio
- GSIW N/A
- BCAB N/A
- Revenue Growth
- GSIW N/A
- BCAB N/A
- 52 Week Low
- GSIW $0.35
- BCAB $0.24
- 52 Week High
- GSIW $12.30
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- GSIW 73.49
- BCAB 45.46
- Support Level
- GSIW $1.39
- BCAB $0.36
- Resistance Level
- GSIW $1.66
- BCAB $0.40
- Average True Range (ATR)
- GSIW 0.15
- BCAB 0.04
- MACD
- GSIW -0.01
- BCAB -0.00
- Stochastic Oscillator
- GSIW 60.80
- BCAB 22.73
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.